Mesothelioma cadherins

Ordonez evaluated 31 epithelioid mesotheliomas and 29 pulmonary adenocarcinomas for E-cadherin and N-cadherin expression. They used the 5H9, HECD-1, and clone 36 anti-E-cadherin antibodies and the 3B9 and clone 32 anti-N-cadherin antibodies.Sixty-eight percent, 52%, and 19% of the epithelial mesotheliomas reacted with anti-E-cadherin clone 36, clone HECD-1, and 5H9, respectively. Seventy-four percent and 71% of epithelial mesotheliomas reacted with anti-N-cadherin clone 3B9 and clone 32, respectively. Ninety-three percent, 90%, and 90% of pulmonary adenocarcinomas reacted with anti-E-cadherin clone 36, clone HECD-1, and clone 5H9, respectively. Forty-five percent and 34% of pulmonary adenocarcinomas reacted with anti-N-cadherin clone 32 and clone 3B9, respectively. Ordonez concluded that the 5H9 anti-E-cadherin antibody had some utility in discriminating between pleural epithelioid mesothelioma and pulmonary adenocarcinoma. 

Leers MPG, Aarts MMJ, Theunissen PHMH. E-cadherin and calretinin A useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathol. 1998 32 209-216. 

Peralta-Soler A, Knudsen KA, Jaurand MC, et al. The differential expression of N-cadherin, E-cadherin distinguished pleural mesotheliomas from lung adenocarcinomas. Hum Pathol. 1995 26 1363-1369. 

Ordonez NG. Value of E-cadherin and N-cadherin immu-nostaining in the diagnosis of mesothelioma. Hum Pathol. 2003 34 749-755. 

---